November 26, 2014

Aethlon Medical Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States

SAN DIEGO, Nov. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today announced the first shipment of Hemopurifier® therapy as a candidate to treat future Ebola virus infections in the United States. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.

Aethlon disclosed that four Hemopurifiers have been shipped to the Biocontainment Unit at the Nebraska Medical Center (NMC) in Omaha as a therapeutic option to be stockpiled for Ebola patients that may be treated at the NMC. Aethlon further disclosed that it has provided onsite training to NMC clinical personnel related to the implementation of Hemopurifier® therapy within the dialysis infrastructure already located at the center.

The Nebraska Biocontainment Unit was commissioned by The United States Centers for Disease Control (CDC) in 2005. It is a joint project involving Nebraska Medicine, Nebraska Health and Human Services, and the University of Nebraska Medical Center. It was designed to provide the first line of treatment for people affected by bioterrorism or extremely infectious naturally occurring diseases such as Ebola. It's the largest facility of its kind in the U.S. The NMC has treated three Ebola patients since the current outbreak. Additional details can be found online at: www.nebraskamed.com/biocontainment-unit

Aethlon previously reported the successful administration of Hemopurifier® therapy to a

Ugandan doctor who was infected with Ebola virus and treated at the Frankfurt University Hospital in Germany. At the time Hemopurifier® therapy was administered, the doctor was unconscious and suffered from multiple organ failure. His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment. The doctor has since made a full recovery and has returned home to his family in Uganda.

In the United States, Hemopurifier® therapy is available to treat Ebola patients through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. Aethlon disclosed that it provided Hemopurifiers to the NMC on a humanitarian basis and therefore will not generate revenues as a result of its initial shipment.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against bioterror and pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

About Aethlon Medical, Inc.

Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent

protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

Leah-Michelle Nebbia (for interviews requests)
Golin
202-585-2651
lnebbia@golin.com

James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

Logo - https://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-announces-first-hemopurifier-shipment-to-support-the-treatment-of-ebola-in-the-united-states-300001546.html

SOURCE Aethlon Medical, Inc.